Arca Biopharma reports almost $67M in cash as it prepares for COVID treatment trials

WESTMINSTER — Arca Biopharma Inc. (Nasdaq: ABIO) said it had almost $67 million in cash on hand at the end of the first quarter of 2021 to fund its clinical research into a possible treatment for some patients with deadly reactions to COVID-19 infections.

The Westminster company reported having just more than $66.93 million in cash and equivalents on hand. It has no revenues, as the company doesn’t have any drugs approved for use by physicians yet.

The company also posted a $4.1 million loss for the period, a 206% increase over the same period last year. The majority of that increased losses came from increased research and development costs.

SPONSORED CONTENT

Exploring & expressing grief

Support groups and events, as well as creative therapies and professional counseling, are all ways in which Pathways supports individuals dealing with grief and loss.

Arca’s flagship drug candidate is AB-201, which was originally designed as an anti-clotting treatment for patients who had suffered heart attacks or other cardiac events. The company repurposed the drug for potential use as an anti-inflammatory and anti-clotting agent to combat those symptoms seen in some patients suffering from severe bouts of COVID-19.

Results for the Phase II trial for AB-201 in COVID patients are due in the third quarter of the year.

© 2021 BizWest Media LLC